TrialRadiation oncology (London, England)2017

Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC).

David A Palma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.